Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

Steven G. Deeks, Stephen J. Gange, Mari M. Kitahata, Michael S. Saag, Amy C. Justice, Robert S. Hogg, Joseph J. Eron, John T. Brooks, Sean B. Rourke, M. John Gill, Ronald J. Bosch, Constance A. Benson, Ann C. Collier, Jeffrey N. Martin, Marina B. Klein, Lisa P. Jacobson, Benigno Rodriguez, Timothy R. Sterling., Gregory D. Kirk, Sonia NapravnikAnita R. Rachlis, Liviana M. Calzavara, Michael A. Horberg, Michael J. Silverberg, Kelly A. Gebo, Margot B. Kushel, James J. Goedert, Rosemary G. McKaig, Richard D. Moore

Research output: Contribution to journalArticle

Abstract

Background: Although combination antiretroviral therapy continues to evolve, with potentially more effective options emerging each year, the ability of therapy to prevent multiple regimen failure and mortality in clinical practice remains poorly defined. Methods: Sixteen cohorts representing over 60 sites contributed data on all individuals who initiated combination antiretroviral therapy. We identified those individuals who experienced virologic failure (defined as a human immunodeficiency virus [HIV] RNA level >1000 copies/mL), received modified therapy, and subsequently had a second episode of virologic failure. Multivariate Cox regression was used to assess factors associated with time to second regimen failure and the time to death after the onset of second regimen failure. Results: Of the 42,790 individuals who received therapy, 7159 experienced a second virologic failure. The risk of second virologic failure decreased from 1996 (56 cases per 100 person-years) through 2005 (16 cases per 100 person-years; P < .001). The cumulative mortality after onset of second virologic failure was 26% at 5 years and decreased over time. A history of AIDS, a lower CD4+ T cell count, and a higher plasma HIV RNA level were each independently associated with mortality. Similar trends were observed when analysis was limited to the subset of previously treatment-naive patients Conclusions: Although the rates of multiple regimen failure have decreased dramatically over the past decade, mortality rates for those who have experienced failure of at least 2 regimens have remained high. Plasma HIV RNA levels, CD4+ T cell counts at time of treatment failure, and a history of AIDS remain independent risk factors for death, which emphasizes that these factors remain important targets for those in need of more-aggressive therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)1582-1590
Number of pages9
JournalClinical Infectious Diseases
Volume49
Issue number10
DOIs
StatePublished - Nov 2009

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America'. Together they form a unique fingerprint.

  • Cite this

    Deeks, S. G., Gange, S. J., Kitahata, M. M., Saag, M. S., Justice, A. C., Hogg, R. S., Eron, J. J., Brooks, J. T., Rourke, S. B., Gill, M. J., Bosch, R. J., Benson, C. A., Collier, A. C., Martin, J. N., Klein, M. B., Jacobson, L. P., Rodriguez, B., Sterling., T. R., Kirk, G. D., ... Moore, R. D. (2009). Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clinical Infectious Diseases, 49(10), 1582-1590. https://doi.org/10.1086/644768